Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK plc (GSK) 13th Annual Jefferies London Healthcare Conference 2022 (Transcript)
09:36pm, Friday, 18'th Nov 2022
GSK plc (NYSE:GSK ) 13th Annual Jefferies London Healthcare Conference 2022 November 16, 2022 4:45 AM ET Company Participants David Redfern - Chief Strategy Officer Conference Call Participants Peter
GSK shares lower as UBS downgrades pharma giant to sell
06:41am, Friday, 11'th Nov 2022
Shares of GSK GSK, -3.85% fell nearly 4% in London as UBS downgraded the pharmaceutical giant to sell from neutral. “We see two factors posing risks to the earnings base longer term – blockbuster
GSK slapped with 'sell' rating over long-term risks
06:32am, Friday, 11'th Nov 2022
GSK PLC (LSE:GSK, NYSE:GSK) shares have been slapped with a 'sell' rating by UBS, which downgraded its recommendation as it sees two big long-term risks ahead. Admittedly, the risks are all the way
GSK: Near-Term Upside
04:58am, Friday, 11'th Nov 2022
British pharmaceutical company GSK has seen an 8% price rise since I wrote about it a little over a month ago. What has driven this? Its upgraded earnings outlook and approvals for its treatments have
GSK second-line applications of new cancer drug will be restricted
02:28am, Friday, 11'th Nov 2022
GSK PLC (LSE:GSK, NYSE:GSK) said the second-line applications of its cancer drug will be limited in scope. The front-line use of Zejula, which has been developed to treat epithelial ovarian, fallopian
GSK spinoff Haleon lifts guidance as revenue rises on higher sales and volumes
02:50am, Thursday, 10'th Nov 2022
By Michael Susin
Bert's October Dividend Income Summary
09:53pm, Wednesday, 09'th Nov 2022
We received $801.63 in October dividend income. This was the first quarter we received a dividend from Vanguard's S&P 500 Index fund (VOO).
GSK slide wipes £2.5bn off its market value, but for one broker this puts the stock in bargain basement territory
10:31am, Monday, 07'th Nov 2022
City broker Shore Capital remained upbeat on the prospects for shares in GSK PLC (LSE:GSK, NYSE:GSK) in spite of the failure of a key clinical trial for a new bone marrow cancer drug. It repeated its
GSK loses almost £1.7bn value after drug trial failure
03:31am, Monday, 07'th Nov 2022
Almost £1.7bn was wiped from the value of GSK PLC (LSE:GSK, NYSE:GSK) in opening deals after the drug developer revealed a late-stage study failed to meet its main goal. Blenrep was deemed no better
Vanguard Health Care Fund Exits Viatris, Plugs Into GSK in 3rd Quarter
06:12pm, Friday, 04'th Nov 2022
The Vanguard Health Care Fund (Trades, Portfolio) disclosed in a regulatory filing that its top trades during the third quarter included the closure of its positions in Viatris Inc. ( VTRS , Financial
GSK's new antibiotic a handy add-on, suggests Deutsche Bank
12:33pm, Friday, 04'th Nov 2022
GSK's experimental fluoroquinolone antibiotic gepotidacin ended its trial early due to its success in treating uncomplicated urinary tract infections (UTIs), the pharma announced this week. Deutsche B
Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit Growth
11:34am, Friday, 04'th Nov 2022
Vir Biotechnology obliterated expectations for its Covid drug in the third quarter, and Vir stock leaped above its 200-day line. The post Vir Obliterates Quarterly Sales Expectations As Covid Drug Del
GSK to submit urinary infection treatment for approval after trial success
04:29am, Thursday, 03'rd Nov 2022
GSK PLC (LSE:GSK, NYSE:GSK) said it was calling an early halt to trials of a new treatment for uncomplicated urinary tract infection (uUTI) because it has already proved its efficacy. An Independent D
GSK vaccine for older adults granted FDA priority review
05:01pm, Wednesday, 02'nd Nov 2022
GSK reported strong third-quarter earnings and raised its forecast for 2022. However worries about Zantac litigation kept investors on edge.
GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up
02:18pm, Wednesday, 02'nd Nov 2022
GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises the full-year sales guidance for all its segment
